Trials / Recruiting
RecruitingNCT06517875
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
A Phase 2 Open-label Study to Evaluate Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Primary or Secondary Myelofibrosis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 56 (estimated)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.
Conditions
- Primary Myelofibrosis
- Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Momelotinib | Momelotinib will be administered orally. |
| DRUG | Luspatercept | Luspatercept will be administered subcutaneously. |
Timeline
- Start date
- 2025-02-28
- Primary completion
- 2026-10-14
- Completion
- 2026-11-13
- First posted
- 2024-07-24
- Last updated
- 2025-12-16
Locations
14 sites across 5 countries: United States, Canada, France, Italy, Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06517875. Inclusion in this directory is not an endorsement.